Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Change in Accured Expenses (2022 - 2025)

Prokidney (PROK) has disclosed Change in Accured Expenses for 4 consecutive years, with $51000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 99.11% to $51000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 3.2% decrease, with the full-year FY2024 number at $11.6 million, changed 0.4% from a year prior.
  • Change in Accured Expenses was $51000.0 for Q3 2025 at Prokidney, up from -$2.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $13.0 million in Q2 2023 to a low of -$5.9 million in Q1 2024.
  • A 4-year average of $1.0 million and a median of $104000.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 739.09% in 2023, then tumbled 2238.46% in 2025.
  • Prokidney's Change in Accured Expenses stood at $533000.0 in 2022, then skyrocketed by 625.14% to $3.9 million in 2023, then surged by 202.87% to $11.7 million in 2024, then plummeted by 99.56% to $51000.0 in 2025.
  • Per Business Quant, the three most recent readings for PROK's Change in Accured Expenses are $51000.0 (Q3 2025), -$2.2 million (Q2 2025), and -$5.9 million (Q1 2025).